Johnson & Johnson (J&J) reported Q3 2023 financial results with total sales of $21.3 billion, a 6.8% increase compared to the same period in 2022. U.S. sales totaled $11.996 billion, an 11.1% increase from 2022. The company also reported a one-time, non-cash gain of around $21 billion related to the final separation of J&J’s consumer health business. The company received several treatment approvals from the FDA and the European Commission, and submitted applications to the European Medicines Agency.